HK1191034A1 - -羧烷基耳他汀類及其應用 - Google Patents
-羧烷基耳他汀類及其應用Info
- Publication number
- HK1191034A1 HK1191034A1 HK14104335.0A HK14104335A HK1191034A1 HK 1191034 A1 HK1191034 A1 HK 1191034A1 HK 14104335 A HK14104335 A HK 14104335A HK 1191034 A1 HK1191034 A1 HK 1191034A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- auristatins
- carboxyalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11158481 | 2011-03-16 | ||
| PCT/EP2012/054294 WO2012123423A1 (de) | 2011-03-16 | 2012-03-12 | N-carboxyalkyl-auristatine und ihre verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1191034A1 true HK1191034A1 (zh) | 2014-07-18 |
Family
ID=45812791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14104335.0A HK1191034A1 (zh) | 2011-03-16 | 2014-05-07 | -羧烷基耳他汀類及其應用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9029406B2 (zh) |
| EP (1) | EP2686336B1 (zh) |
| JP (2) | JP6023097B2 (zh) |
| CN (1) | CN103764667B (zh) |
| CA (1) | CA2829736C (zh) |
| ES (1) | ES2543888T3 (zh) |
| HK (1) | HK1191034A1 (zh) |
| WO (1) | WO2012123423A1 (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012041805A1 (de) | 2010-09-29 | 2012-04-05 | Bayer Pharma Aktiengesellschaft | N-carboxyalkyl-auristatine und ihre verwendung |
| WO2012143499A2 (de) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
| SI2780039T1 (en) | 2011-11-17 | 2018-06-29 | Pfizer Inc. | Cytotoxic peptides and their conjugates between the antibody and the drug |
| US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| AU2014364812B2 (en) | 2013-12-17 | 2017-05-25 | Novartis Ag | Cytotoxic peptides and conjugates thereof |
| CA2935077C (en) | 2013-12-27 | 2022-03-15 | Geoffrey C. Winters | Sulfonamide-containing linkage systems for drug conjugates |
| SI3134124T1 (sl) | 2014-04-25 | 2019-06-28 | Pierre Fabre Medicament | Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka |
| MX2016013999A (es) | 2014-04-25 | 2017-05-30 | Pf Medicament | Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer. |
| CA2951368A1 (en) | 2014-06-13 | 2015-12-17 | Novartis Ag | Auristatin derivatives and conjugates thereof |
| CN111393346B (zh) * | 2020-06-02 | 2020-08-25 | 凯莱英生命科学技术(天津)有限公司 | N-Boc-Dolaproine及Boc-Dap DCHA的合成方法 |
| CA3230737A1 (en) | 2021-09-03 | 2023-03-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| CA2315230C (en) | 1998-01-09 | 2004-06-29 | Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University | Anti-cryptococcal peptides |
| JP2002544242A (ja) | 1999-05-14 | 2002-12-24 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 酵素活性化抗腫瘍プロドラッグ化合物 |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| US6884869B2 (en) * | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6737409B2 (en) * | 2001-07-19 | 2004-05-18 | Hoffmann-La Roche Inc. | Dolastatin 10 derivatives |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| KR101520209B1 (ko) * | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| US8288352B2 (en) | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
| CA2614436C (en) | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| SI2502938T1 (sl) | 2006-10-27 | 2015-05-29 | Genentech, Inc. | Protitelesa in imunokonjugati in njihove uporabe |
| NO2842575T3 (zh) | 2008-03-18 | 2018-02-24 | ||
| ES2528956T3 (es) | 2010-06-10 | 2015-02-13 | Seattle Genetics, Inc. | Nuevos derivados de auristatina y su uso |
| WO2012041805A1 (de) * | 2010-09-29 | 2012-04-05 | Bayer Pharma Aktiengesellschaft | N-carboxyalkyl-auristatine und ihre verwendung |
| WO2012143499A2 (de) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
-
2012
- 2012-03-12 CN CN201280019732.4A patent/CN103764667B/zh active Active
- 2012-03-12 EP EP12708034.9A patent/EP2686336B1/de active Active
- 2012-03-12 WO PCT/EP2012/054294 patent/WO2012123423A1/de active Application Filing
- 2012-03-12 US US14/004,699 patent/US9029406B2/en active Active
- 2012-03-12 ES ES12708034.9T patent/ES2543888T3/es active Active
- 2012-03-12 JP JP2013558400A patent/JP6023097B2/ja active Active
- 2012-03-12 CA CA2829736A patent/CA2829736C/en active Active
-
2014
- 2014-05-07 HK HK14104335.0A patent/HK1191034A1/zh unknown
-
2016
- 2016-07-25 JP JP2016145282A patent/JP2016185987A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2829736C (en) | 2020-07-21 |
| CA2829736A1 (en) | 2012-09-20 |
| US20140080763A1 (en) | 2014-03-20 |
| CN103764667A (zh) | 2014-04-30 |
| CN103764667B (zh) | 2017-06-20 |
| ES2543888T3 (es) | 2015-08-25 |
| EP2686336A1 (de) | 2014-01-22 |
| JP2014515735A (ja) | 2014-07-03 |
| US9029406B2 (en) | 2015-05-12 |
| EP2686336B1 (de) | 2015-05-06 |
| JP6023097B2 (ja) | 2016-11-09 |
| JP2016185987A (ja) | 2016-10-27 |
| WO2012123423A1 (de) | 2012-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2100012I1 (hu) | 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók | |
| IL233051A0 (en) | Anti-phf-tau antibodies and uses thereof | |
| HK1187049A1 (zh) | 雙芳基連接的芳基三唑酮及其用途 | |
| EP2739695A4 (en) | ADHESIVES AND THEIR USE | |
| IL229844B (en) | Anti-psgl-1 antibodies and their use | |
| HK1191034A1 (zh) | -羧烷基耳他汀類及其應用 | |
| GB201111705D0 (en) | Compounds and their use | |
| GB201110783D0 (en) | Methods and uses | |
| IL231082A0 (en) | Pyrimido-pyridazinone compounds and their use | |
| EP2688588A4 (en) | FAST AND LONG-TERM IMMUNOLOGICAL THERAPEUTIC | |
| GB201116774D0 (en) | Uses and methods | |
| GB201111630D0 (en) | Novel compounds and their use | |
| EP2697386A4 (en) | DESIGN AND USE OF PEPDUCINE | |
| EP2716359A4 (en) | COMPLEX AND USES THEREOF | |
| GB201111775D0 (en) | Compounds and uses thereof | |
| GB201114448D0 (en) | Compounds and their use | |
| EP2693879A4 (en) | MIGRASTATINES AND THEIR USES | |
| HK1198587A1 (zh) | 異噻唑並吡啶- -甲酰胺和它們作為藥物的用途 | |
| GB201108490D0 (en) | Methods and uses | |
| GB201104444D0 (en) | Compounds and their use | |
| GB201119443D0 (en) | GoWinging Concept and patent | |
| PT2734522T (pt) | 4-imidazopiridazina-1-il-benzamidas e 4-imidazotriazin-1- il-benzamidas como inibidores de btk | |
| GB201121726D0 (en) | Compounds and uses thereof | |
| GB201121551D0 (en) | Compounds and uses thereof |